Efficacy of hyperthermic intraperitoneal chemotherapy in colorectal cancer: A phase I and III open label randomized controlled registry-based clinical trial protocol

Autor: Lana Ghanipour, Gabriella Jansson Palmer, Per J. Nilsson, Caroline Nordenvall, Jan-Erik Frödin, Elinor Bexe Lindskog, Dan Asplund, Torbjörn Swartling, Wilhelm Graf, Helgi Birgisson, Ingvar Syk, Victor Verwaal, Jenny Brändstedt, Peter H. Cashin

Publikováno v: PLoS ONE, Vol 19, Iss 3 (2024)

Externí odkaz: https://doaj.org/article/e36fa431cccd4e7f8ea365924f4f0e3b

Readmissions after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy—a national population-based study

Autor: Paul Dranichnikov, Wilhelm Graf, Peter H. Cashin

Publikováno v: World Journal of Surgical Oncology, Vol 18, Iss 1, Pp 1-8 (2020)

Abstract Background Comprehensive readmission morbidity studies after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are scarce. This study aimed to investigate readmissions and in-hospital morbidity after CRS and H

Externí odkaz: https://doaj.org/article/72c22efc6ad5476ea515d7ee304704c5

The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

Autor: Brendan Moran, John Spiliotis, Paul H. Sugarbaker, Claudio Almeida Quadros, Yutaka Yonemura, Santiago González-Moreno, Yan Li, Vincent C J van de Vlasakker, Marcello Deraco, Robin J. Lurvink, Wim Ceelen, Kuno Lehmann, Ignace H. J. T. de Hingh, Melissa Ching Ching Teo, David L. Morris, S.P. Somashekhar, Kurt Van der Speeten, Vic J. Verwaal, Antonio Sommariva, Olivier Glehen, Peter H Cashin, Beate Rau, Pompiliu Piso, Diane Goéré

Publikováno v: European Journal of Surgical Oncology, 47(11), 2888-2892. ELSEVIER SCI LTD
van de Vlasakker, V C J, Lurvink, R J, Cashin, P H, Ceelen, W, Deraco, M, Goéré, D, González-Moreno, S, Lehmann, K, Li, Y, Moran, B, Morris, D L, Piso, P, Quadros, C A, Rau, B, Somashekhar, S P, Sommariva, A, van der Speeten, K, Spiliotis, J, Sugarbaker, P H, Teo, M C C, Verwaal, V J, Yonemura, Y, Glehen, O & de Hingh, I H J T 2021, ' The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases : A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI) ', European Journal of Surgical Oncology, vol. 47, no. 11, pp. 2888-2892 . https://doi.org/10.1016/j.ejso.2021.05.023

Introduction: The PRODIGE 7-trial investigated the additional value of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to cytoreductive surgery (CRS) for patients with colorectal peritoneal metastases (CPM). The results of PRODIGE 7 were presented

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b0527b75136cdc9e398df26b5d24bd
https://doi.org/10.1016/j.ejso.2021.05.023

Prognostic Impact of BRAF and KRAS Mutation in Patients with Colorectal and Appendiceal Peritoneal Metastases Scheduled for CRS and HIPEC

Autor: Alexei Terman, Wilhelm Graf, Helgi Birgisson, Peter H Cashin, Johan Botling, Lana Ghanipour, Malin Enblad

Publikováno v: Annals of Surgical Oncology. 27:293-300

Background KRAS and BRAF mutations are prognostic and predictive tools in metastatic colorectal cancer, but little is known about their prognostic value in patients scheduled for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemothera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d0069e7aa3b8c3d1f966c6397ff5f4c
https://doi.org/10.1245/s10434-019-07452-2

The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma

Autor: Rosella Bertulli, Ingvar Syk, Julien Péron, Marc Pocard, Pierre Dubé, M. Deraco, Eun Jung Park, Kuno Lehmann, Mohammad Alyami, Almog Ben-Yaacov, Marcos Lyra, Vahan Kepenekian, Selman Sökmen, Jason M. Foster, Yang Yu, Filippo Pietrantonio, B. J. Moran, Stein Gunnar Larsen, Brian W. Loggie, Peter J. Hewett, Marianne Sinn, Claudio Almeida Quadros, Martin Hübner, Yutaka Yonemura, NielsF.M. Kok, S. Kusamura, Lucas Sideris, Malcom S. Wilson, Luis Gonzales-Bayon, Paul H. Sugarbaker, Pedro Barrios-Sanchez, Jacobus W. A. Burger, John Spiliotis, Delia Cortes-Guiral, Pankaj K. Pande, Maciej S. Nowacki, Olivier Glehen, Armando Sardi, Mao-Chih Hsieh, Robin J. Lurvink, Aviram Nissan, Yan Li, Wim Ceelen, Craig Lynch, MelissaC.C. Teo, Sanket Mehta, Sanjeev Dayal, Peter C. Thuss-Patience, Jan Braess, Aditi Bhatt, Firoz Rajan, Victor J. Verwaal, Michele De Simone, Thierry André, Laurent Villeneuve, Beate Rau, A.A.K. Tentes, Mario Valle, Geert-Jan Creemers, K. Van der Speeten, Jasen Ly, Kiran K. Turaga, Maria Di Bartolomeo, P.A. Cascales-Campos, Marc A. Reymond, Joel M. Baumgartner, Faheez Mohamed, S.P. Somashekhar, David L. Morris, Peter H Cashin, Pompiliu Piso, Roman Yarema, Diane Goéré, Kjersti Flatmark, K. Govaerts, David J. Perry, P Tom Cecil, I. H. J. T. de Hingh, Nicholas Lutton, Alexander G. Heriot

Publikováno v: Lurvink, R J, Villeneuve, L, Govaerts, K, de Hingh, I H J T, Moran, B J, Deraco, M, Van der Speeten, K, Glehen, O, Kepenekian, V, Kusamura, S & List of PSOGI collaborators 2021, ' The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on Pseudomyxoma Peritonei and Peritoneal Mesothelioma ', European Journal of Surgical Oncology, vol. 47, no. 1, pp. 4-10 . https://doi.org/10.1016/j.ejso.2019.03.012
European Journal of Surgical Oncology

Pseudomyxoma Peritonei (PMP) and Peritoneal Mesothelioma (PM) are both rare peritoneal malignancies. Currently, affected patients may be treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy offering long-term survival or e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e026f5aac72ab2ed519822fc5ea7c1aa
https://avesis.deu.edu.tr/publication/details/d24f3b87-9cd6-4632-a0fe-a2aba5993db7/oai